Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.57 |
| ▸ | PPARG | P37231 | 2/20 | 0.57 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.52 |
| ▸ | CFD | P00746 | 1/20 | 0.49 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.47 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.47 |
| ▸ | KAT8 | Q9H7Z6 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.43 |
| ▸ | TUBB | P07437 | 1/20 | 0.43 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.43 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.43 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31006902 | 1.00 | PPARA (0.57) | PPARAPPARGMRGPRX4CFDCYP4A11 | |
| SCHEMBL26104257 | 0.90 | MRGPRX4 (0.55) | PPARAPPARGMRGPRX4CFDCYP4A11 | |
| SCHEMBL31135560 | 0.90 | MRGPRX4 (0.55) | PPARAPPARGMRGPRX4CFDCYP4A11 | |
| SCHEMBL14398158 | 0.88 | PPARA (0.69) | PPARAPPARGMRGPRX4CFDKAT8 | |
| SCHEMBL12505396 | 0.86 | TNKS2 (0.46) | PPARAPPARGCYP4A11TNKS2KDM4E | |
| SCHEMBL30394546 | 0.86 | CYP4A11 (0.58) | PPARAPPARGCYP4A11TNKS2KDM4E | |
| SCHEMBL26101039 | 0.86 | CYP4A11 (0.58) | PPARAPPARGCYP4A11TNKS2KDM4E | |
| SCHEMBL20521861 | 0.86 | PPARA (0.56) | PPARAPPARGMRGPRX4CFDCYP4A11 | |
| SCHEMBL11731466 | 0.85 | PPARA (0.79) | PPARAPPARGKAT8 | |
| SCHEMBL20522149 | 0.84 | PPARG (0.60) | PPARAPPARGMRGPRX4CFDKAT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630541-B2 | Compounds useful as inhibitors of ALCAT 1 | PERENNA PHARMACEUTICALS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4448508-A1 | BENZOTHIOPHENE DERIVATIVES AS RXFP1 AGONISTS | Bristol-Myers Squibb Company (US) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023114819-A1 | TETRALINE, PHENYLCYCLOBUTANE, AND PHENYLCYCLOPENTANE ANALOGS AS RXFP1 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023114823-A1 | BENZOTHIOPHENE DERIVATIVES AS RXFP1 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023114823-A1 | BENZOTHIOPHENE DERIVATIVES AS RXFP1 AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-06-22 | — | — | WO | disclosed |
| US-20220089582-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ALCAT 1 | PERENNA PHARMACEUTICALS, INC. | 2022-03-24 | — | — | US | disclosed |
| US-11208404-B2 | Compounds useful as inhibitors of ALCAT 1 | PERENNA PHARMACEUTICALS, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20200109136-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ALCAT 1 | PERENNA PHARMACEUTICALS, INC. | 2020-04-09 | — | — | US | disclosed |
| EP-3601274-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ALCAT 1 | Perenna Pharmaceuticals, Inc. (US) | 2020-02-05 | — | — | EP | disclosed |
| CN-110709394-A | Compounds useful as ALCAT1 inhibitors | 中美博瑞纳制药有限公司 | 2020-01-17 | — | — | CN | disclosed |
| WO-2018178304-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ALCAT 1 | PERENNA PHARMACEUTICALS, INC. (US) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089582-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ALCAT 1 | ACAT1, ACAT2, SLC33A1 | PPARA 361/4885PPARG 374/4885MRGPRX4 4203/4885 |
| US-12630541-B2 | Compounds useful as inhibitors of ALCAT 1 | LCLAT1, LPCAT1, ACAT2 | PPARA 994/4885PPARG 1062/4885MRGPRX4 4291/4885 |
| US-11208404-B2 | Compounds useful as inhibitors of ALCAT 1 | ACAT1, ACAT2, SLC33A1 | PPARA 361/4885PPARG 374/4885MRGPRX4 4203/4885 |
| US-20200109136-A1 | COMPOUNDS USEFUL AS INHIBITORS OF ALCAT 1 | ACAT1, ACAT2, SLC33A1 | PPARA 361/4885PPARG 374/4885MRGPRX4 4203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.